These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29340807)

  • 41. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS; Richardson P; Castillo D; Kane SV
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
    Tighe D; McNamara D
    World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
    Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
    Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Vaughn BP; Osterman MT; Cheifetz AS
    J Crohns Colitis; 2018 Jun; 12(7):804-810. PubMed ID: 29590345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
    Sasson AN; Ananthakrishnan AN
    Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
    Wong U; Cross RK
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
    AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
    Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
    Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
    Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
    Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
    Baert F; Drobne D; Gils A; Vande Casteele N; Hauenstein S; Singh S; Lockton S; Rutgeerts P; Vermeire S
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.